248 related articles for article (PubMed ID: 26885368)
1. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.
Nelson MH; Bowers JS; Bailey SR; Diven MA; Fugle CW; Kaiser AD; Wrzesinski C; Liu B; Restifo NP; Paulos CM
J Immunother Cancer; 2016; 4():6. PubMed ID: 26885368
[TBL] [Abstract][Full Text] [Related]
2. B cells imprint adoptively transferred CD8
Smith AS; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Rivera-Reyes AM; Dwyer CJ; Ware MB; Cole AC; Neskey DM; Rubinstein MP; Liu B; Thaxton JE; Bartee E; Paulos CM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017148
[TBL] [Abstract][Full Text] [Related]
3. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
[TBL] [Abstract][Full Text] [Related]
4. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
Paulos CM; Wrzesinski C; Kaiser A; Hinrichs CS; Chieppa M; Cassard L; Palmer DC; Boni A; Muranski P; Yu Z; Gattinoni L; Antony PA; Rosenberg SA; Restifo NP
J Clin Invest; 2007 Aug; 117(8):2197-204. PubMed ID: 17657310
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.
Amos SM; Pegram HJ; Westwood JA; John LB; Devaud C; Clarke CJ; Restifo NP; Smyth MJ; Darcy PK; Kershaw MH
Cancer Immunol Immunother; 2011 May; 60(5):671-83. PubMed ID: 21327636
[TBL] [Abstract][Full Text] [Related]
6. Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
Ng SSM; Nagy BA; Jensen SM; Hu X; Alicea C; Fox BA; Felber BK; Bergamaschi C; Pavlakis GN
Clin Cancer Res; 2017 Jun; 23(11):2817-2830. PubMed ID: 27986749
[No Abstract] [Full Text] [Related]
7. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8
Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM; Wrangle JM; Cole DJ; Rubinstein MP
Cancer Res; 2018 Jun; 78(11):3067-3074. PubMed ID: 29636345
[TBL] [Abstract][Full Text] [Related]
8. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.
He H; Wisner P; Yang G; Hu HM; Haley D; Miller W; O'Hara A; Alvord WG; Clegg CH; Fox BA; Urba WJ; Walker EB
J Transl Med; 2006 Jun; 4():24. PubMed ID: 16772043
[TBL] [Abstract][Full Text] [Related]
9. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
10. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptors in tumor immunotherapy.
Paulos CM; Kaiser A; Wrzesinski C; Hinrichs CS; Cassard L; Boni A; Muranski P; Sanchez-Perez L; Palmer DC; Yu Z; Antony PA; Gattinoni L; Rosenberg SA; Restifo NP
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5280-9. PubMed ID: 17875756
[TBL] [Abstract][Full Text] [Related]
12. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
[TBL] [Abstract][Full Text] [Related]
13. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
14. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
15. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
Gattinoni L; Finkelstein SE; Klebanoff CA; Antony PA; Palmer DC; Spiess PJ; Hwang LN; Yu Z; Wrzesinski C; Heimann DM; Surh CD; Rosenberg SA; Restifo NP
J Exp Med; 2005 Oct; 202(7):907-12. PubMed ID: 16203864
[TBL] [Abstract][Full Text] [Related]
16. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
17. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
Wrzesinski C; Paulos CM; Kaiser A; Muranski P; Palmer DC; Gattinoni L; Yu Z; Rosenberg SA; Restifo NP
J Immunother; 2010 Jan; 33(1):1-7. PubMed ID: 19952961
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
Cancer Immunol Immunother; 2006 Apr; 55(4):420-32. PubMed ID: 16025264
[TBL] [Abstract][Full Text] [Related]
19. Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
bioRxiv; 2023 Dec; ():. PubMed ID: 38187594
[TBL] [Abstract][Full Text] [Related]
20. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.
Sorrentino R; Morello S; Forte G; Montinaro A; De Vita G; Luciano A; Palma G; Arra C; Maiolino P; Adcock IM; Pinto A
Am J Respir Crit Care Med; 2011 May; 183(10):1369-79. PubMed ID: 21278302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
